Nucleic acid-based theranostics in type 1 diabetes

Bennett Francis Dwan; Anna Moore; Ping Wang

doi:10.1016/j.trsl.2019.08.006

Nucleic acid-based theranostics in type 1 diabetes

Transl Res. 2019 Dec:214:50-61. doi: 10.1016/j.trsl.2019.08.006. Epub 2019 Aug 21.

Authors

Bennett Francis Dwan¹, Anna Moore², Ping Wang³

Affiliations

¹ Precision Health Program, Department of Radiology, College of Human Medicine, Michigan State University, East Lansing, Michigan; College of Natural Science, Michigan State University, East Lansing, Michigan.
² Precision Health Program, Department of Radiology, College of Human Medicine, Michigan State University, East Lansing, Michigan.
³ Precision Health Program, Department of Radiology, College of Human Medicine, Michigan State University, East Lansing, Michigan. Electronic address: wangpin4@msu.edu.

PMID: 31491371
DOI: 10.1016/j.trsl.2019.08.006

Abstract

Application of RNAi interference for type 1 diabetes (T1D) therapy bears tremendous potential. This review will discuss vehicles for oligonucleotide delivery, imaging modalities used for delivery monitoring, therapeutic targets, and different theranostic strategies that can be applied for T1D treatment.

Publication types

Review

MeSH terms

Diabetes Mellitus, Type 1 / therapy*
Graft Rejection / immunology
Humans
Islets of Langerhans / metabolism
Molecular Targeted Therapy
Nucleic Acids / therapeutic use*
Theranostic Nanomedicine*

Substances

Nucleic Acids